Open-label study to evaluate the pharmacodynamics, clinical efficacy, and safety of meropenem for adult bacterial meningitis in Japan

Akihiko Morita, Satoshi Kamei, Masayuki Minami, Kazuto Yoshida, Satoshi Kawabata, Hiroshi Kuroda, Yasushi Suzuki, Nobuo Araki, Yasuo Iwasaki, Rei Kobayashi, Naoki Hayashi, Tetsuyuki Hirayama, Jun Ochiai, Miki Ueda, Yuka Yamagishi, Jun Ichi Niwa, Katsuro Shindo, Yoshihisa Fukushima, Tomohiro Takita, Takayuki Sato & 3 others Shigeru Sato, Hiroshige Mikamo, Satoshi Iwata

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The aim of this study was to assess the efficacy, safety, and concentration of meropenem in cerebrospinal fluid when meropenem (2 g every 8 h) was administered to Japanese adult patients with bacterial meningitis. Five Japanese patients (mean age 60.6 years [range 35-71]) were enrolled. Infection with Streptococcus pneumoniae (three patients), Streptococcus salivarius (one patient), and Staphylococcus aureus (one patient) was confirmed by cerebrospinal fluid culture. Meropenem (2 g every 8 h) was administered to all five patients. Treatment duration ranged from 14 to 28 days (mean 22.6 days). All the patients were successfully treated. The concentration of meropenem in cerebrospinal fluid ranged from 0.27 to 6.40 μg/ml up to 8.47 h and was over 1 μg/ml 3 h after starting meropenem infusion. In each patient, the present study confirmed for the first time that the concentration of meropenem in cerebrospinal fluid exceeded the minimal inhibitory concentration for these pathogens. Eleven clinical and laboratory adverse events considered to be related to meropenem were observed in all patients, but no serious adverse event and no discontinuance of treatment due to adverse events occurred. Thus meropenem appeared to be a well-tolerated and effective agent for Japanese adult patients with bacterial meningitis. 2 g every 8 h of meropenem was delivered to CSF and its concentration was exceed in MICs for the detected pathogens.

Original languageEnglish
Pages (from-to)535-540
Number of pages6
JournalJournal of Infection and Chemotherapy
Volume20
Issue number9
DOIs
Publication statusPublished - 2014

Fingerprint

meropenem
Bacterial Meningitides
Japan
Safety
Cerebrospinal Fluid
Pneumococcal Infections

Keywords

  • Adult
  • Bacterial meningitis
  • Efficacy
  • Japanese
  • Meropenem
  • Safety

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases
  • Medicine(all)

Cite this

Open-label study to evaluate the pharmacodynamics, clinical efficacy, and safety of meropenem for adult bacterial meningitis in Japan. / Morita, Akihiko; Kamei, Satoshi; Minami, Masayuki; Yoshida, Kazuto; Kawabata, Satoshi; Kuroda, Hiroshi; Suzuki, Yasushi; Araki, Nobuo; Iwasaki, Yasuo; Kobayashi, Rei; Hayashi, Naoki; Hirayama, Tetsuyuki; Ochiai, Jun; Ueda, Miki; Yamagishi, Yuka; Niwa, Jun Ichi; Shindo, Katsuro; Fukushima, Yoshihisa; Takita, Tomohiro; Sato, Takayuki; Sato, Shigeru; Mikamo, Hiroshige; Iwata, Satoshi.

In: Journal of Infection and Chemotherapy, Vol. 20, No. 9, 2014, p. 535-540.

Research output: Contribution to journalArticle

Morita, A, Kamei, S, Minami, M, Yoshida, K, Kawabata, S, Kuroda, H, Suzuki, Y, Araki, N, Iwasaki, Y, Kobayashi, R, Hayashi, N, Hirayama, T, Ochiai, J, Ueda, M, Yamagishi, Y, Niwa, JI, Shindo, K, Fukushima, Y, Takita, T, Sato, T, Sato, S, Mikamo, H & Iwata, S 2014, 'Open-label study to evaluate the pharmacodynamics, clinical efficacy, and safety of meropenem for adult bacterial meningitis in Japan', Journal of Infection and Chemotherapy, vol. 20, no. 9, pp. 535-540. https://doi.org/10.1016/j.jiac.2014.04.013
Morita, Akihiko ; Kamei, Satoshi ; Minami, Masayuki ; Yoshida, Kazuto ; Kawabata, Satoshi ; Kuroda, Hiroshi ; Suzuki, Yasushi ; Araki, Nobuo ; Iwasaki, Yasuo ; Kobayashi, Rei ; Hayashi, Naoki ; Hirayama, Tetsuyuki ; Ochiai, Jun ; Ueda, Miki ; Yamagishi, Yuka ; Niwa, Jun Ichi ; Shindo, Katsuro ; Fukushima, Yoshihisa ; Takita, Tomohiro ; Sato, Takayuki ; Sato, Shigeru ; Mikamo, Hiroshige ; Iwata, Satoshi. / Open-label study to evaluate the pharmacodynamics, clinical efficacy, and safety of meropenem for adult bacterial meningitis in Japan. In: Journal of Infection and Chemotherapy. 2014 ; Vol. 20, No. 9. pp. 535-540.
@article{ce8610cb535848149e8a0417e6578b3c,
title = "Open-label study to evaluate the pharmacodynamics, clinical efficacy, and safety of meropenem for adult bacterial meningitis in Japan",
abstract = "The aim of this study was to assess the efficacy, safety, and concentration of meropenem in cerebrospinal fluid when meropenem (2 g every 8 h) was administered to Japanese adult patients with bacterial meningitis. Five Japanese patients (mean age 60.6 years [range 35-71]) were enrolled. Infection with Streptococcus pneumoniae (three patients), Streptococcus salivarius (one patient), and Staphylococcus aureus (one patient) was confirmed by cerebrospinal fluid culture. Meropenem (2 g every 8 h) was administered to all five patients. Treatment duration ranged from 14 to 28 days (mean 22.6 days). All the patients were successfully treated. The concentration of meropenem in cerebrospinal fluid ranged from 0.27 to 6.40 μg/ml up to 8.47 h and was over 1 μg/ml 3 h after starting meropenem infusion. In each patient, the present study confirmed for the first time that the concentration of meropenem in cerebrospinal fluid exceeded the minimal inhibitory concentration for these pathogens. Eleven clinical and laboratory adverse events considered to be related to meropenem were observed in all patients, but no serious adverse event and no discontinuance of treatment due to adverse events occurred. Thus meropenem appeared to be a well-tolerated and effective agent for Japanese adult patients with bacterial meningitis. 2 g every 8 h of meropenem was delivered to CSF and its concentration was exceed in MICs for the detected pathogens.",
keywords = "Adult, Bacterial meningitis, Efficacy, Japanese, Meropenem, Safety",
author = "Akihiko Morita and Satoshi Kamei and Masayuki Minami and Kazuto Yoshida and Satoshi Kawabata and Hiroshi Kuroda and Yasushi Suzuki and Nobuo Araki and Yasuo Iwasaki and Rei Kobayashi and Naoki Hayashi and Tetsuyuki Hirayama and Jun Ochiai and Miki Ueda and Yuka Yamagishi and Niwa, {Jun Ichi} and Katsuro Shindo and Yoshihisa Fukushima and Tomohiro Takita and Takayuki Sato and Shigeru Sato and Hiroshige Mikamo and Satoshi Iwata",
year = "2014",
doi = "10.1016/j.jiac.2014.04.013",
language = "English",
volume = "20",
pages = "535--540",
journal = "Journal of Infection and Chemotherapy",
issn = "1341-321X",
publisher = "Elsevier BV",
number = "9",

}

TY - JOUR

T1 - Open-label study to evaluate the pharmacodynamics, clinical efficacy, and safety of meropenem for adult bacterial meningitis in Japan

AU - Morita, Akihiko

AU - Kamei, Satoshi

AU - Minami, Masayuki

AU - Yoshida, Kazuto

AU - Kawabata, Satoshi

AU - Kuroda, Hiroshi

AU - Suzuki, Yasushi

AU - Araki, Nobuo

AU - Iwasaki, Yasuo

AU - Kobayashi, Rei

AU - Hayashi, Naoki

AU - Hirayama, Tetsuyuki

AU - Ochiai, Jun

AU - Ueda, Miki

AU - Yamagishi, Yuka

AU - Niwa, Jun Ichi

AU - Shindo, Katsuro

AU - Fukushima, Yoshihisa

AU - Takita, Tomohiro

AU - Sato, Takayuki

AU - Sato, Shigeru

AU - Mikamo, Hiroshige

AU - Iwata, Satoshi

PY - 2014

Y1 - 2014

N2 - The aim of this study was to assess the efficacy, safety, and concentration of meropenem in cerebrospinal fluid when meropenem (2 g every 8 h) was administered to Japanese adult patients with bacterial meningitis. Five Japanese patients (mean age 60.6 years [range 35-71]) were enrolled. Infection with Streptococcus pneumoniae (three patients), Streptococcus salivarius (one patient), and Staphylococcus aureus (one patient) was confirmed by cerebrospinal fluid culture. Meropenem (2 g every 8 h) was administered to all five patients. Treatment duration ranged from 14 to 28 days (mean 22.6 days). All the patients were successfully treated. The concentration of meropenem in cerebrospinal fluid ranged from 0.27 to 6.40 μg/ml up to 8.47 h and was over 1 μg/ml 3 h after starting meropenem infusion. In each patient, the present study confirmed for the first time that the concentration of meropenem in cerebrospinal fluid exceeded the minimal inhibitory concentration for these pathogens. Eleven clinical and laboratory adverse events considered to be related to meropenem were observed in all patients, but no serious adverse event and no discontinuance of treatment due to adverse events occurred. Thus meropenem appeared to be a well-tolerated and effective agent for Japanese adult patients with bacterial meningitis. 2 g every 8 h of meropenem was delivered to CSF and its concentration was exceed in MICs for the detected pathogens.

AB - The aim of this study was to assess the efficacy, safety, and concentration of meropenem in cerebrospinal fluid when meropenem (2 g every 8 h) was administered to Japanese adult patients with bacterial meningitis. Five Japanese patients (mean age 60.6 years [range 35-71]) were enrolled. Infection with Streptococcus pneumoniae (three patients), Streptococcus salivarius (one patient), and Staphylococcus aureus (one patient) was confirmed by cerebrospinal fluid culture. Meropenem (2 g every 8 h) was administered to all five patients. Treatment duration ranged from 14 to 28 days (mean 22.6 days). All the patients were successfully treated. The concentration of meropenem in cerebrospinal fluid ranged from 0.27 to 6.40 μg/ml up to 8.47 h and was over 1 μg/ml 3 h after starting meropenem infusion. In each patient, the present study confirmed for the first time that the concentration of meropenem in cerebrospinal fluid exceeded the minimal inhibitory concentration for these pathogens. Eleven clinical and laboratory adverse events considered to be related to meropenem were observed in all patients, but no serious adverse event and no discontinuance of treatment due to adverse events occurred. Thus meropenem appeared to be a well-tolerated and effective agent for Japanese adult patients with bacterial meningitis. 2 g every 8 h of meropenem was delivered to CSF and its concentration was exceed in MICs for the detected pathogens.

KW - Adult

KW - Bacterial meningitis

KW - Efficacy

KW - Japanese

KW - Meropenem

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=84906306432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906306432&partnerID=8YFLogxK

U2 - 10.1016/j.jiac.2014.04.013

DO - 10.1016/j.jiac.2014.04.013

M3 - Article

VL - 20

SP - 535

EP - 540

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

SN - 1341-321X

IS - 9

ER -